Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Bevacizumab Stereotactic Radiotherapy

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01392209Phase 1Completed

Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

Showing all 1 trials

Research Network

Common Treatments

  • Bevacizumab Stereotactic Radiotherapy1

Active Sponsors

  • Columbia University1
  • Memorial Sloan Kettering Cancer Center1
  • Genentech, Inc.1
  • University of California, San Francisco1

Top Investigators

Related Conditions

  • Anaplastic Astrocytoma Aa1
  • Brain Cancer1
  • Anaplastic Oligodendroglioma Ao1
  • Glioblastoma1
  • Malignant Glioma1

Activity Timeline